QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

PHAT

QT73Phathom Pharmaceuticals, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
10.88
-0.12-1.09%
OverviewShort InterestFilings
PHATQT73Phathom Pharmaceuticals, Inc.·NASDAQ
OverviewShort InterestFilings
10.88-1.09%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-2.12
Insider Own33.09%
Shs Outstand79.76M
Perf Week5.94%
Market Cap877.31MForward P/E9.14EPS next Y1.19Insider Trans0.07%Shs Float-Perf Month-4.56%
Enterprise Value862.71MPEG-EPS next Q-0.20Inst Own-Short Float-Perf Quarter-2.42%
Income-152915987.00P/S4.28EPS this Y70.60%Inst Trans-Short Ratio-Perf Half Y-28.61%
Sales204.89MP/B-EPS next Y291.03%ROA-51.55%Short Interest-Perf YTD-34.42%
Book/sh-4.23P/C-EPS next 5Y-ROE39.24%52W High18.31 -40.58%Perf Year3.62%
Cash/sh2.27P/FCF-EPS past 3/5Y-ROIC-53.45%52W Low7.61 42.97%Perf 3Y-
Dividend Est.-EV/EBITDA-9.49Sales past 3/5Y-Gross Margin84.93%Volatility3.56% 4.05%Perf 5Y-
Dividend TTM-EV/Sales4.21EPS Y/Y TTM72.21%Oper. Margin-47.15%ATR (14)0.69Perf 10Y-
Dividend Ex-Date-Quick Ratio2.16Sales Y/Y TTM274.55%Profit Margin-76.77%RSI (14)51.70Recom1.75
Dividend Gr. 3/5Y-Current Ratio2.21EPS Q/Q65.42%SMA205.16%Beta1.00Target Price23.00
Payout0.00%Debt/Eq-0.49Sales Q/Q100.00%SMA50-5.46%Rel Volume0.89Prev Close11.00
Employees427LT Debt/Eq-0.48EarningsAug 06SMA200-14.77%Avg Volume1.24MPrice10.88
IPO DateOct 25, 2019Option/ShortYes / YesEPS/Sales Surpr.-37.04% 3.57%Net Debt/EBITDA0.16Volume1,101,340Change-1.09%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-27-26UpgradeBarclaysEqual Weight → Overweight$16 → $18
Feb-26-26ReiteratedStifel Nicolaus$24 → $28
Dec-11-25InitiatedRaymond JamesStrong Buy$28
Dec-08-25InitiatedBarclaysEqual Weight$16
Oct-31-25ReiteratedCraig-HallumBuy$17 → $22
Oct-31-25ReiteratedH.C. Wainwright$20 → $26
Oct-30-25ReiteratedGuggenheimBuy$18 → $20
Mar-07-25ReiteratedGuggenheimBuy$28 → $18
Jul-19-24ReiteratedH.C. Wainwright$28
May-02-24InitiatedStifelBuy$24
Latest News
Jun-17-26
Jun-17-2606:24AM
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price TargetBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue20617555
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A31238
Gross Profit17315347
Selling, General and Administrative Excl. Other239280291
Research and Development313334
Other Operating Expense1-10
Operating Income-96-160-277
Interest Expense666872
Unusual Expense
———
Non-Operating Income (Expense)-5-7-15
Net Income Before Taxes-157-221-334
Income Taxes
000
Consolidated Net Income-157-221-334
Net Income From Continuing Operations-157-221-334
Net Income-157-221-334
EPS (Recurring)-2.12-3.03-5.29
EPS (Basic, Before Extraordinaries)-2.12-3.03-5.29
EPS (Diluted)-2.12-3.03-5.29
EBITDA-91-152-262
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio4.336.92—
Gross Margin83.9887.4385.45
Operating Margin-46.60-91.43-503.64
Net Margin-76.21-126.29-607.27
Shares Outstanding827363
Market Capitalization8921,211—
Operating Lease Expense
———
Insider Trading Volume
$12.05$11.29$10.52$9.75$8.99● Close Price0.00K3.54K7.08K10.61K14.15KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Parikh AsitDirectorMay 20 '26Option Exercise4.9517,50086,62552,122May 21 12:00 AM
Parikh AsitDirectorJan 13 '26Option Exercise10.3017,500180,250131,000Jan 15 12:00 AM
Parikh AsitDirectorDec 19 '25Option Exercise10.3017,500180,250122,250Dec 23 12:00 AM
Basta Steven LPresident and CEONov 28 '25Option Exercise0.00180,0000180,000Dec 02 12:00 AM
Breedlove Robert CharlesPrincipal Accounting OfficerNov 03 '25Sale13.515247,07947,407Nov 05 12:00 AM
Basta Steven LPresident and CEOSep 25 '25Option Exercise0.00180,0000270,000Sep 26 12:00 AM
Breedlove Robert CharlesPrincipal Accounting OfficerSep 05 '25Sale12.094615,57347,931Sep 09 12:00 AM
Breedlove Robert CharlesPrincipal Accounting OfficerJul 16 '25Sale8.361,69214,15248,392Jul 18 12:00 AM
Topper James NDirectorMay 21 '25Buy3.863,78014,60959,403May 23 12:00 AM
Topper James NDirectorMay 14 '25Buy3.326,30020,91955,623May 15 12:00 AM
Topper James NDirectorMay 13 '25Buy3.161,1203,54349,323May 15 12:00 AM
Topper James NDirectorMay 12 '25Buy3.0412,60138,30148,203May 13 12:00 AM
Topper James NDirectorMay 09 '25Buy3.2235,602114,61635,602May 13 12:00 AM
Parikh AsitDirectorMay 07 '25Buy2.405,00011,98595,500May 08 12:00 AM
Parikh AsitDirectorMay 06 '25Buy2.605,00013,00090,500May 08 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR